<DOC>
	<DOCNO>NCT01746771</DOCNO>
	<brief_summary>[ Phase I ] The main objective study evaluate safety , tolerability determine Recommended Dose ( RD ) HM781-36B ( Poziotinib ) combine Paclitaxel Trastuzumab [ Phase II ] The main objective study evaluate anticancer activity determination response rate HM781-36B ( Poziotinib ) combine Paclitaxel Trastuzumab patient HER-2 positive advance gastric cancer</brief_summary>
	<brief_title>A Phase I-II Study HM781-36B Combined With Paclitaxel Trastuzumab HER-2 Positive Advanced Gastric Cancer</brief_title>
	<detailed_description>Besides main objective , objective follow : [ Phase I ] 1 . To assess pharmacokinetic profile HM781-36B ( Poziotinib ) combine Paclitaxel Trastuzumab 2 . To evaluate anticancer activity HM781-36B ( Poziotinib ) combine Paclitaxel Trastuzumab patient HER-2 positive advance gastric cancer 3 . To evaluate PFS ( Progression-Free Survival ) , TTP ( Time To Tumor Progression ) , DOR ( Duration Overall Response ) [ Phase II ] 1 . To assess safety , tolerability HM781-36B ( Poziotinib ) combine Paclitaxel Trastuzumab 2 . To evaluate tumor response determination disease control rate , PFS ( Progression-Free Survival ) , TTP ( Time To Tumor Progression ) , DOR ( Duration Overall Response )</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Histologically cytologically confirm advanced gastric cancer include gastroesophageal junction adenocarcinoma 2 . At least one measurable lesion define RECIST ( v1.1 ) 3 . FISH+ IHC3+ ( regardless FISH result ) 4 . Age≥19 5 . ECOG ≤ 2 6 . Life expectancy ≥ 12 week 7 . Adequate bone marrow abnormal heart lung function 8 . No radiotherapy , anticancer drug immunotherapy allow study 9 . Subjects must provide write informed consent prior performance study specific procedure assessment , must willing comply treatment follow assessment procedures 1 . Patients history hypersensitivity Trastuzumab treat medicine include Cremophor EL 2 . Patients current active malignancy gastric adenocarcinoma ( exception nonmelanoma skin cancer cervical cancer situ ) 3 . Patients previously receive taxanebased chemotherapy 4 . The presence central nervous system metastases 5 . Patients blood tumor leukemia , previously receive , plan receive , bone marrow transplant 6 . Patients uncontrolled infection 7 . Patients GI malabsorption difficulty take oral medication 8 . Patients follow disease exclude : 9 . Patients psychiatric congenital disorder affect adherence make hard follow requirement protocol 10 . Pregnant breastfeed woman woman childbearing use appropriate method contraception ( male patient also use appropriate method contraception )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>HM781-36B , Paclitaxel , Trastuzumab</keyword>
</DOC>